CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase 1 Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) and Nivolumab in Patients With MDS or Low Blast Count AML
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT03358719
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:28:19.913230+00:00
- Published At
- 2026-02-27T00:00:00+00:00
- Record Updated At
- 2026-02-27
- Results Posted At
- 2026-02-27
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Acute Myeloid Leukemia", "Blasts 30 Percent or Less of Bone Marrow Nucleated Cells", "Chronic Myelomonocytic Leukemia", "High Risk Myelodysplastic Syndrome", "Myelodysplastic Syndrome", "Refractory Anemia"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-02-27"- protocolSection.identificationModule.nctId
"NCT03358719"- protocolSection.identificationModule.officialTitle
"A Phase 1 Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Conjunction With 5-Aza-2\u0027Deoxycytidine (Decitabine) and Nivolumab in Patients With MDS or Low Blast Count AML"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2026-02-27"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.